Advisory Research Inc. continued to hold its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 63,423 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Advisory Research Inc. owned about 0.06% of Lexicon Pharmaceuticals worth $909,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State of Wisconsin Investment Board bought a new stake in Lexicon Pharmaceuticals in the 2nd quarter valued at approximately $510,000. Highbridge Capital Management LLC bought a new stake in Lexicon Pharmaceuticals in the 1st quarter valued at approximately $7,813,000. Pictet Asset Management Ltd. lifted its stake in Lexicon Pharmaceuticals by 10.4% in the 2nd quarter. Pictet Asset Management Ltd. now owns 67,950 shares of the biopharmaceutical company’s stock valued at $941,000 after acquiring an additional 6,400 shares in the last quarter. First Mercantile Trust Co. lifted its stake in Lexicon Pharmaceuticals by 11.2% in the 2nd quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after acquiring an additional 1,227 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in Lexicon Pharmaceuticals by 11.1% in the 1st quarter. Wellington Management Group LLP now owns 279,874 shares of the biopharmaceutical company’s stock valued at $4,013,000 after acquiring an additional 27,964 shares in the last quarter.
Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded down 0.79% on Friday, hitting $11.26. The company had a trading volume of 24,729 shares. The stock’s market capitalization is $1.19 billion. Lexicon Pharmaceuticals, Inc. has a one year low of $11.22 and a one year high of $18.00. The stock has a 50 day moving average of $13.09 and a 200-day moving average of $14.89.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The company had revenue of $12.00 million for the quarter, compared to analyst estimates of $18.34 million. During the same period last year, the company posted ($0.37) earnings per share. Lexicon Pharmaceuticals’s revenue was down 40.3% compared to the same quarter last year. Equities analysts anticipate that Lexicon Pharmaceuticals, Inc. will post ($1.47) EPS for the current year.
In other news, insider Lonnel Coats purchased 30,000 shares of the business’s stock in a transaction on Friday, September 15th. The shares were acquired at an average cost of $12.54 per share, with a total value of $376,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.77% of the stock is currently owned by insiders.
Several research analysts have weighed in on the company. BidaskClub lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Wedbush reaffirmed an “outperform” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, October 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $28.75.
TRADEMARK VIOLATION NOTICE: “Advisory Research Inc. Maintains Position in Lexicon Pharmaceuticals, Inc. (LXRX)” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.themarketsdaily.com/2017/10/13/advisory-research-inc-maintains-position-in-lexicon-pharmaceuticals-inc-lxrx.html.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.